<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811263</url>
  </required_header>
  <id_info>
    <org_study_id>P0511976</org_study_id>
    <nct_id>NCT02811263</nct_id>
  </id_info>
  <brief_title>High-dose Erythropoietin for Asphyxia and Encephalopathy</brief_title>
  <acronym>HEAL</acronym>
  <official_title>High-dose Erythropoietin for Asphyxia and Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mednax Center for Research, Education, Quality and Safety</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cook Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoxic-ischemic encephalopathy (HIE) occurs when a baby gets reduced blood flow and oxygen&#xD;
      to the brain near the time of birth. This results in death or neurologic disabilities&#xD;
      including cerebral palsy and cognitive impairment in up to half of affected infants. This&#xD;
      clinical trial will determine if the drug erythropoietin (Epo) added to hypothermia (usual&#xD;
      therapy) will improve outcomes for infants suffering from HIE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neonatal hypoxic-ischemic encephalopathy (HIE) refers to brain injury resulting from reduced&#xD;
      blood and oxygen flow to a baby's brain near the time of birth. HIE affects up to 12,000&#xD;
      newborns each year in the U.S. Half of affected infants have a bad outcome including death,&#xD;
      cerebral palsy and cognitive impairment despite receiving hypothermia, the only available&#xD;
      treatment. Erythropoietin (Epo) is a cytokine with remarkable neuroprotective and&#xD;
      neuroregenerative effects demonstrated in animal models of neonatal brain injury. In a phase&#xD;
      I trial of Epo + hypothermia, the investigators found that Epo 1000 U/Kg/dose best reproduced&#xD;
      the pharmacokinetics of neuroprotective dosing in animal models. Long term outcomes were&#xD;
      better than expected based on entry criteria and MRI findings. A phase II trial compared 50&#xD;
      cooled infants randomized to receive Epo or placebo. Infants treated with hypothermia + Epo&#xD;
      had less brain injury on early MRI, and better 12-month motor development. The investigators&#xD;
      hypothesize that Epo given to cooled infants with moderate/severe HIE will reduce the&#xD;
      combined primary outcome of death or neurodevelopmental impairment from 49 to 33%. This is a&#xD;
      randomized, double-blind, placebo-controlled trial of Epo therapy in 500 infants with HIE&#xD;
      undergoing hypothermia. Specific aims are 1) To determine if 5 doses of Epo 1000 U/kg IV&#xD;
      reduces the rate of death, motor or cognitive deficits at 2 years; 2) To assess safety of Epo&#xD;
      by evaluating clinical toxicity; and 3) To determine whether Epo decreases the severity of&#xD;
      neonatal brain injury as evidenced by early MRI and circulating biomarkers of brain injury.&#xD;
      The investigators anticipate that Epo will confer improved 2-year neurodevelopmental outcome,&#xD;
      will be safe, and will decrease brain injury severity as determined by early biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or neurodevelopmental impairment</measure>
    <time_frame>Prior to final outcome assessment at 22-26 months of age; For extenuating circumstances, for example, COVID-19 restrictions, may be performed up to 36 months of age</time_frame>
    <description>Neurodevelopmental impairment defined as any of the following: a) Gross Motor Function Scale (GMFCS) level ≥ 1, or b) GMFCS = 0 or 0.5 and cerebral palsy (CP) (any type), or c) Bayley III Cognitive Score &lt; 90</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence and type of cerebral palsy (CP) determined using a standardized neurologic examination</measure>
    <time_frame>22-26 months; For extenuating circumstances, for example, COVID-19 restrictions, may be performed up to 36 months of age</time_frame>
    <description>Neurologic diagnoses: no CP, diparetic CP, hemiparetic CP, quadriparetic CP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of gross motor function determined using the GMFCS</measure>
    <time_frame>22-26 months; For extenuating circumstances, for example, COVID-19 restrictions, may be performed up to 36 months of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bayley III cognitive and language scores</measure>
    <time_frame>22-26 months; For extenuating circumstances, for example, COVID-19 restrictions, may be performed up to 36 months of age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of epilepsy</measure>
    <time_frame>Prior to 22-26 months</time_frame>
    <description>≥ 2 afebrile, unprovoked seizures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral abnormalities determined by the externalizing score of the Child Behavior Checklist</measure>
    <time_frame>22-26 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Rates of Epo-related adverse events</measure>
    <time_frame>Through hospital discharge</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rates of Epo-related adverse events</measure>
    <time_frame>Through 22-26 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serial circulating biomarkers of inflammation/brain injury</measure>
    <time_frame>During first week of life</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MR evidence of brain injury</measure>
    <time_frame>During first week of life</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">501</enrollment>
  <condition>Neonatal Encephalopathy</condition>
  <condition>Birth Asphyxia</condition>
  <arm_group>
    <arm_group_label>Erythropoietin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Erythropoietin 1000 U/kg IV, at about 1, 2, 3, 4, and 7 days of age (i.e., 5 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline IV (equal volume), at about 1, 2, 3, 4, and 7 days of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline placebo</intervention_name>
    <description>Equal volume of normal saline to be used as placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>Epogen drawn from commercially available single dose 4000U/mL vials</description>
    <arm_group_label>Erythropoietin</arm_group_label>
    <other_name>Epogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 36 weeks of gestational age&#xD;
&#xD;
          -  Receiving active or passive whole body cooling/hypothermia since &lt; 6 hours of age&#xD;
&#xD;
          -  Perinatal depression based on at least one of the following:&#xD;
&#xD;
               1. Apgar score &lt; 5 at 10 minutes, or&#xD;
&#xD;
               2. Need for resuscitation at 10 minutes (i.e., chest compressions, or positive&#xD;
                  pressure respiratory support including endotracheal, mask ventilation, or CPAP),&#xD;
                  or&#xD;
&#xD;
               3. pH &lt; 7.00 in cord gas (arterial or venous) or in an infant gas (arterial or&#xD;
                  venous) obtained at &lt; 60 minutes of age, or&#xD;
&#xD;
               4. Base deficit ≥ 15 mmol/L in cord gas (arterial or venous) or in an infant gas&#xD;
                  (arterial or venous) obtained at &lt; 60 minutes of age&#xD;
&#xD;
          -  Moderate to severe encephalopathy (based on modified Sarnat exam) present between 1-6&#xD;
             hours after birth&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Study drug unlikely to be administered within 26 hours of birth&#xD;
&#xD;
          -  Infant has living twin (or higher order multiple) who is also being cooled&#xD;
&#xD;
          -  Birth weight &lt; 1800 g (e.g., intrauterine growth restriction)&#xD;
&#xD;
          -  Genetic or congenital condition that affects neurodevelopment or requires multiple&#xD;
             surgeries (e.g., congenital viral infection, hydrops, complex congenital heart&#xD;
             disease, severe dysmorphic features, etc.)&#xD;
&#xD;
          -  Head circumference &lt; 30 cm&#xD;
&#xD;
          -  Redirection of care is being considered due to moribund condition&#xD;
&#xD;
          -  Patient anticipated to be unavailable for evaluation at age 2&#xD;
&#xD;
          -  Polycythemia (hematocrit &gt; 65.0%)&#xD;
&#xD;
          -  Parents/legal guardians with diminished capacity and autonomy&#xD;
&#xD;
          -  Infant is participating or intends to participate in another interventional study&#xD;
             during the birth hospitalization (note: does not include observational studies)&#xD;
&#xD;
          -  Sentinel event and encephalopathy occurred only after birth&#xD;
&#xD;
          -  Unable to consent in primary language of parent(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne Wu, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Juul, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota: Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota: St. Paul</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee Women's Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Juul SE, Comstock BA, Heagerty PJ, Mayock DE, Goodman AM, Hauge S, Gonzalez F, Wu YW. High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL): A Randomized Controlled Trial - Background, Aims, and Study Protocol. Neonatology. 2018;113(4):331-338. doi: 10.1159/000486820. Epub 2018 Mar 7.</citation>
    <PMID>29514165</PMID>
  </reference>
  <reference>
    <citation>Wisnowski JL, Bluml S, Panigrahy A, Mathur AM, Berman J, Chen PK, Dix J, Flynn T, Fricke S, Friedman SD, Head HW, Ho CY, Kline-Fath B, Oveson M, Patterson R, Pruthi S, Rollins N, Ramos YM, Rampton J, Rusin J, Shaw DW, Smith M, Tkach J, Vasanawala S, Vossough A, Whitehead MT, Xu D, Yeom K, Comstock B, Heagerty PJ, Juul SE, Wu YW, McKinstry RC; HEAL Study Group. Integrating neuroimaging biomarkers into the multicentre, high-dose erythropoietin for asphyxia and encephalopathy (HEAL) trial: rationale, protocol and harmonisation. BMJ Open. 2021 Apr 22;11(4):e043852. doi: 10.1136/bmjopen-2020-043852.</citation>
    <PMID>33888528</PMID>
  </reference>
  <results_reference>
    <citation>Wu YW, Mathur AM, Chang T, McKinstry RC, Mulkey SB, Mayock DE, Van Meurs KP, Rogers EE, Gonzalez FF, Comstock BA, Juul SE, Msall ME, Bonifacio SL, Glass HC, Massaro AN, Dong L, Tan KW, Heagerty PJ, Ballard RA. High-Dose Erythropoietin and Hypothermia for Hypoxic-Ischemic Encephalopathy: A Phase II Trial. Pediatrics. 2016 Jun;137(6). pii: e20160191. doi: 10.1542/peds.2016-0191. Epub 2016 May 2.</citation>
    <PMID>27244862</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, Chang T, Durand DJ, Song D, Bonifacio SL, Gonzalez FF, Glass HC, Juul SE. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics. 2012 Oct;130(4):683-91. doi: 10.1542/peds.2012-0498. Epub 2012 Sep 24.</citation>
    <PMID>23008465</PMID>
  </results_reference>
  <results_reference>
    <citation>Chalak L, Redline RW, Goodman AM, Juul SE, Chang T, Yanowitz TD, Maitre N, Mayock DE, Lampland AL, Bendel-Stenzel E, Riley D, Mathur AM, Rao R, Van Meurs KP, Wu TW, Gonzalez FF, Flibotte J, Mietzsch U, Sokol GM, Ahmad KA, Baserga M, Weitkamp JH, Poindexter BB, Comstock BA, Wu YW. Acute and Chronic Placental Abnormalities in a Multicenter Cohort of Newborn Infants with Hypoxic-Ischemic Encephalopathy. J Pediatr. 2021 Oct;237:190-196. doi: 10.1016/j.jpeds.2021.06.023. Epub 2021 Jun 16.</citation>
    <PMID>34144032</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Yvonne Wu</investigator_full_name>
    <investigator_title>Professor of Neurology and Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Asphyxia Neonatorum</mesh_term>
    <mesh_term>Asphyxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

